Drug Trial Radar · NCT06839235
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
23
Planned (sponsor's estimate)
Start
Jun 16, 2025
Primary completion
Mar 2029
Study completion Feb 2043
Sponsor
- Lead sponsor
- Arbor BiotechnologiesIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long-term monitoring program to comply with local and national requirements.
Conditions
- Primary Hyperoxaluria Type 1 (PH1)
Interventions
ABO-101Drug
Intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs), including ABO-101-related TEAEs and serious adverse events (SAEs)Time frame: Up to 6 months
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota · Recruiting
Nucleus Network
Saint Paul, Minnesota · Withdrawn
Hospices Civils de Lyon- Hôpital Femmes Mères Enfants
Lyon, France · Not yet recruiting
Kindernierenzentrum Bonn
Bonn, Germany · Not yet recruiting
Heidi Chaker
Sfax, Tunisia · Recruiting
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom · Recruiting
Royal Free Hospital
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.